67 results found.

Renal Cell Carcinoma Clinical Trial using everolimus and bevacizumab

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC).
everolimus and bevacizumab

Carcinoma, Renal Cell Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting 18 years or older.
- Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma.
Sorafenib (Nexavar, BAY43-9006)

Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, or Clinical Trial using cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study Comparing Cabozantinib With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.
cabozantinib-s-malate; sunitinib malate; laboratory biomarker analysis

Renal Cell Carcinoma Clinical Trial using Cabozantinib (XL184); Everolimus (Afinitor)

Exelixis - Recruiting 18 years or older.
- A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy.
Cabozantinib (XL184); Everolimus (Afinitor)

Renal Cell Carcinoma Clinical Trial using MPDL3280A; bevacizumab [Avastin]; sunitinib

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, RANDOMIZED STUDY OF MPDL3280A ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA.
MPDL3280A; bevacizumab [Avastin]; sunitinib

Advanced Renal Cell Carcinoma, Renal Cell Carcinoma, or Metastati Clinical Trial using Standard Treatment; AGS-003

Argos Therapeutics - Recruiting 18 years or older.
- An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT).
Standard Treatment; AGS-003

Metastatic Renal Cell Carcinoma Clinical Trial using RAD001

Novartis - Recruiting 18 years or older.
- An Open-label, Multicenter Phase II Study to Examine the Efficacy and Safety of Everolimus as Second-line Therapy in the Treatment of Patients With Metastatic Renal Cell Carcinoma.
RAD001

Carcinoma, Renal Cell, or Lymphoma, Mantle-Cell Clinical Trial using Temsirolimus (Non-Interventional Study)

Pfizer - Recruiting 18 years or older.
- INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus.
Temsirolimus (Non-Interventional Study)

Renal Cell Carcinoma(RCC) Clinical Trial using Anlotinib hydrochloric capsule

Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd - Recruiting 18 years to 75 years.
- A Phase II Study of Anlotinib(AL3818) Hydrochloric Capsule in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy.
Anlotinib hydrochloric capsule

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

Anlotinib, or RCC Clinical Trial using Anlotinib hydrochloric capsule; Sunitinib maleate

Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd - Recruiting 18 years to 75 years.
- A Randomized, Positive-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) Hydrochloric Capsule in Patients With Advanced Renal Cell Carcinoma(RCC).
Anlotinib hydrochloric capsule; Sunitinib maleate

Metastatic Renal Cell Carcinoma Clinical Trial using Sunitinib

VU University Medical Center - Recruiting 18 years or older.
- Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma.
Sunitinib

Renal Cell Carcinoma, Breast Cancer, Colon Cancer, Lung Cancer, o Clinical Trial using dimethane sulfonate (DMS612, NSC 281612)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase 1, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612, NSC 281612) in Advanced Malignancies.
dimethane sulfonate (DMS612, NSC 281612)

Hemangioblastoma, Hereditary Neoplastic Syndrome, Hippel Lindau D Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders.

Renal Cell Carcinoma, Graft-Versus-Host Disease, or Engraftment S Clinical Trial using Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells.
Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

Renal Cell Carcinoma Clinical Trial using Bevacizumab; Ixempra (Ixbepilone [BMS-247550]

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase II Multi-Center Study of Bevacizumab in Combination With Ixabepilone in Subjects With Advanced Renal Cell Carcinoma.
Bevacizumab; Ixempra (Ixbepilone [BMS-247550]

Carcinoma, Renal Cell Clinical Trial using Pazopanib

GlaxoSmithKline - Recruiting 18 years or older.
- PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib.
Pazopanib

Renal Cell Carcinoma Clinical Trial using Arterial Spin Labeling Magnetic Resonance Imaging

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Antiangiogenic and Targeted Therapies of Metastatic Renal Cell Carcinoma.
Arterial Spin Labeling Magnetic Resonance Imaging

Clear Cell Renal Cell Carcinoma, or Stage IV Renal Cell Cancer Clinical Trial using entinostat; aldesleukin; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18; positron emission tomography; computed tomography

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma.
entinostat; aldesleukin; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18; positron emission tomography; computed tomography

Colorectal Cancers Clinical Trial using RENCA macrobeads

The Rogosin Institute - Recruiting 18 years or older.
- A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma.
RENCA macrobeads

Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Sta Clinical Trial using bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Bevacizumab Alone or in Combination With TRC 105 for Advanced Renal Cell Cancer.
bevacizumab; anti-endoglin monoclonal antibody TRC105; laboratory biomarker analysis; pharmacological study

Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, or Gastro Clinical Trial using Temsirolimus; Sunitinib; Axitinib

Pfizer - Recruiting 18 years or older.
- STAR-TOR - Registry for the Evaluation of the Safety, Tolerability and Efficacy of Temsirolimus (Toriselr), Sunitinib (Sutentr), and Axitnib (Inlytar) for the Treatment of Subjects With Advanced Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), and Gastro-Intestinal Stroma Tumor (GIST).
Temsirolimus; Sunitinib; Axitinib

Renal Cell Carcinoma Clinical Trial using Temsirolimus

Pfizer - Recruiting N/A or older.
- Torisel Special Investigation (Regulatory Post Marketing Commitment Plan).
Temsirolimus

Renal Cell Carcinoma Clinical Trial using Temsirolimus

Pfizer - Recruiting N/A or older.
- Torisel Drug Use Investigation (Regulatory Post Marketing Commitment Plan).
Temsirolimus

Renal Cell Carcinoma Clinical Trial using questionnaire

Mayo Clinic - Recruiting 18 years or older.
- Renal Mass Registry.
questionnaire

Carcinoma, Renal Cell, Non Clear Cell Renal Carcinoma, Papillary Clinical Trial using RAD001

Novartis - Recruiting 18 years or older.
- A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer.
RAD001

Carcinoma, Renal Cell Clinical Trial using Pazopanib; MK-3475

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma.
Pazopanib; MK-3475

Renal Cell Carcinoma Clinical Trial using Pazopanib

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- A Phase II Study of Pazopanib in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC) Who Have Failed Prior Sunitinib Therapy.
Pazopanib

Renal Cell Carcinoma Clinical Trial using Everolimus; GDC-0980

Genentech - Recruiting 18 years or older.
- A Phase II, Open Label, Randomized Study of GDC-0980 Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following VEGF-Targeted Therapy.
Everolimus; GDC-0980

Renal Cell Carcinoma Clinical Trial using No intervention

Bayer - Recruiting 18 years or older.
- Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma.
No intervention

Carcinoma, Hepatocellular, or Carcinoma, Renal Cell Clinical Trial using Sorafenib (Nexavar, BAY43-9006)

Bayer - Recruiting N/A or older.
- Regulatory Post Marketing Surveillance Study on Nexavarr.
Sorafenib (Nexavar, BAY43-9006)

Advanced or Metastatic (Medically or Surgically Unresectable) Cle Clinical Trial using Nivolumab; Everolimus

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy.
Nivolumab; Everolimus

Carcinoma, Renal Cell Clinical Trial using Sorafenib( Nexavar, BAY43-9006)

Bayer - Recruiting 65 years or older.
- Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib.
Sorafenib( Nexavar, BAY43-9006)

Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage Clinical Trial using pazopanib hydrochloride; therapeutic conventional surgery

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Pazopanib to Enable Partial Nephrectomy.
pazopanib hydrochloride; therapeutic conventional surgery

Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Ca Clinical Trial using Cisplatin; Gemcitabine; ALT-801

Altor Bioscience Corporation - Recruiting 18 years or older.
- A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer.
Cisplatin; Gemcitabine; ALT-801

Renal Cell Carcinoma Clinical Trial using BKM-120 Bevacizumab

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of Bevacizumab and Escalation Doses of BKM-120 in Patients With Metastatic Renal Cell Carcinoma Who Failed Prior Systemic Therapies.
BKM-120 Bevacizumab

Renal Cell Carcinoma Clinical Trial using CyberKnife. SBRT

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma.
CyberKnife. SBRT

Kidney Cancer Clinical Trial using aldesleukin; bevacizumab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Study of Bevacizumab and Aldesleukin in Patients With Metastatic Renal Cell Carcinoma (RCC): A Cytokine Working Group (CWG) Study.
aldesleukin; bevacizumab

Kidney Cancer Clinical Trial using sunitinib malate; gene expression analysis; reverse transcriptase-polymerase chain reaction; western blotting; immunohistochemistry staining method; laboratory biomarker analysis; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma.
sunitinib malate; gene expression analysis; reverse transcriptase-polymerase chain reaction; western blotting; immunohistochemistry staining method; laboratory biomarker analysis; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

Kidney Cancer Clinical Trial using motexafin gadolinium; sunitinib malate; comparative genomic hybridization; gene expression analysis; mutation analysis; polymorphism analysis; immunohistochemistry staining method; iodine I-124 girentuximab; laboratory biomarker analysis; pharmacological study; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Histopathologic and Imaging Study of Renal Cell Carcinoma Vasculature in the Setting of Sunitinib Therapy Prior to Cytoreductive Nephrectomy.
motexafin gadolinium; sunitinib malate; comparative genomic hybridization; gene expression analysis; mutation analysis; polymorphism analysis; immunohistochemistry staining method; iodine I-124 girentuximab; laboratory biomarker analysis; pharmacological study; adjuvant therapy; neoadjuvant therapy; therapeutic conventional surgery

Renal Cell Carcinoma Clinical Trial using Axitinib

PrECOG, LLC. - Recruiting 18 years or older.
- NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC).
Axitinib

Pre- and Postoperative Analgesia, Spinal Anesthesia, or Renal Cel Clinical Trial using klonidin; epidural anesthesia

Ume† University - Recruiting 18 years or older.
- Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma.
klonidin; epidural anesthesia

Kidney Cancer Clinical Trial using Pazopanib; Temsirolimus; Quality of Life Assessment; Benadryl

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma.
Pazopanib; Temsirolimus; Quality of Life Assessment; Benadryl

Renal Cancer Clinical Trial using 124IcG250

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma.
124IcG250

Kidney Cancer Clinical Trial using Bevacizumab; Temsirolimus

Hellenic Cooperative Oncology Group - Recruiting 18 years or older.
- Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Temsirolimus, After 1st Line Anti-VEGF Treatment in Patients With Advanced Renal Cancer.
Bevacizumab; Temsirolimus

Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Sta Clinical Trial using ziv-aflibercept; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study to Determine the Effect of 2 Different Doses AVE0005 (VEGF Trap) in Patients With Metastatic Renal Cell Carcinoma.
ziv-aflibercept; laboratory biomarker analysis

Distal Urethral Cancer, Metastatic Transitional Cell Cancer of th Clinical Trial using gemcitabine hydrochloride; cisplatin; placebo; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma.
gemcitabine hydrochloride; cisplatin; placebo; bevacizumab; laboratory biomarker analysis

Kidney Cancer Clinical Trial using Pazopanib; Bevacizumab; Everolimus

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial.
Pazopanib; Bevacizumab; Everolimus

Metastatic Clear Cell Renal Cell Carcinoma Clinical Trial using IL-2; Stereotactic Ablative Body Radiation Therapy

University of Texas Southwestern Medical Center - Recruiting 18 years or older.
- A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Metastatic Clear Cell Renal Cell Cancer (mRCC).
IL-2; Stereotactic Ablative Body Radiation Therapy

Clear Cell, Metastatic Renal Cell Carcinoma Clinical Trial using Sunitinib

Sunnybrook Health Sciences Centre - Recruiting 18 years or older.
- A Phase II, Multi-Centre, Study of the Efficacy and Safety of Sunitinib Given on an Individualized Schedule as First-Line Therapy for Metastatic Renal Cell Cancer.
Sunitinib

Kidney Cancer Clinical Trial using Evaluation

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Phase II Metastasectomy Study for Patients With Renal Cell Carcinoma..
Evaluation

Carcinoma, Renal Cell Clinical Trial

Assistance Publique - H“pitaux de Paris - Recruiting 18 years to 85 years.
- Medical and Economical Impact of Predicting the Response to Anti-angiogenic Treatment in Metastatic Renal Cell Carcinoma Using Functional CT and MRI.

Recurrent Renal Cell Cancer, or Stage IV Renal Cell Cancer Clinical Trial using stereotactic body radiation therapy; therapeutic conventional surgery; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- Immunologic Impact of Stereotactic Body Radiation Therapy (SBRT) in Renal Cell Carcinoma.
stereotactic body radiation therapy; therapeutic conventional surgery; laboratory biomarker analysis

Kidney Cancer Clinical Trial using gene expression analysis; protein expression analysis; diagnostic laboratory biomarker analysis; immunoenzyme technique; immunohistochemistry staining method

City of Hope Medical Center - Recruiting N/A or older.
- Development of a Blood Test of Anti-IMP3 Autoantibody for the Detection of Renal Cell Carcinoma With Metastasis and Metastatic Potential.
gene expression analysis; protein expression analysis; diagnostic laboratory biomarker analysis; immunoenzyme technique; immunohistochemistry staining method

Oral Mucositis, Renal Cell Carcinoma, Hepatocellular Carcinoma, o Clinical Trial using supersaturated calcium-phosphate rinse; sodium chloride 0.9 %

Waterland Hospital - Recruiting 18 years or older.
- Phase III Randomized Double-blind Cross-over Trial of Caphosolr Versus NaCl 0.9% in the Relief of Oral Mucositis in Renal Cell Carcinoma, Hepatocellular Carcinoma, and Gastrointestinal Stromal Tumor Patients Receiving Targeted Therapy.
supersaturated calcium-phosphate rinse; sodium chloride 0.9 %

Renal Cell Carcinoma, or Zero Ischemia Clinical Trial using zero ischemia laparoscopic RFA assisted TE; ischemia

RenJi Hospital - Recruiting 15 years to 80 years.
- Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage : Clinical Outcomes of a Randomised Controlled Trial.
zero ischemia laparoscopic RFA assisted TE; ischemia

Renal Cell Carcinoma Clinical Trial using sorafenib+gemcitabine+cisplatin

Beijing Cancer Hospital - Recruiting 18 years to 70 years.
- Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma:A Pilot, Open Study.
sorafenib+gemcitabine+cisplatin

Patients With Newly Diagnosed Small Renal Masses(<4cm) Clinical Trial

University Health Network, Toronto - Recruiting 18 years or older.
- Role of Active Surveillance and Identification of Prognostic Factors for Progression in Early Stage Renal Cell Carcinoma.

Kidney Cancer Clinical Trial using everolimus

Baylor College of Medicine - Recruiting 18 years or older.
- Neoadjuvant Everolimus(RAD001)for Advanced RCC Before Cytoreductive Nephrectomy, With Correlative Tumor Studies (Protocol #: 06-08-20-01).
everolimus

Renal Cell Carcinoma Clinical Trial using Progressive strength training

German Cancer Research Center - Recruiting 18 years or older.
- Pilot Study on the Effects of Strength Training on Cancer Related Fatigue in Patients With Renal Cell Carcinoma Under Tyrosin Kinase Inhibitor Therapy.
Progressive strength training

Renal Cell Carcinoma, or Pulmonary Metastases Clinical Trial using Sunitinib; Placebo

Association of Urogenital Oncology (AUO) - Recruiting 18 years to 75 years.
- Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie ber 1 Jahr SMAT - AN 20/04 Der AUO.
Sunitinib; Placebo

Hepatocellular Carcinoma, or Renal Cell Carcinoma Clinical Trial

Samsung Medical Center - Recruiting N/A or older.
- Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma.

Clear Cell Renal Cell Carcinoma, or Metastasis Clinical Trial using Sunitinib

Korean Urological Oncology Society - Recruiting 18 years or older.
- Neoadjuvant Sunitinib Therapy in Patients With Metastatic Clear Cell Type Renal Cell Carcinoma Patients: a Prospective Study.
Sunitinib

Renal Cell Carcinoma, Kidney Neoplasm, Renal Cancer, or Kidney Ca Clinical Trial using Yttrium-90 conjugated chimeric G250 (90Y-cG250)

Ludwig Institute for Cancer Research - Recruiting N/A or older.
- Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Chimeric Monoclonal Antibody cG250 (90Y-DOTA-cG250) in Patients With Advanced Renal Cancer.
Yttrium-90 conjugated chimeric G250 (90Y-cG250)

Carcinoma, Renal Cell Clinical Trial using Radiofrequency ablation; Interferon-alpha; Radiofrequency ablation; Sunitinib maleate; Sunitinib maleate

Kidney Cancer Research Bureau - Recruiting 18 years to 85 years.
- Phase II Trial of Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients With Small Primary Tumor.
Radiofrequency ablation; Interferon-alpha; Radiofrequency ablation; Sunitinib maleate; Sunitinib maleate

Renal Cell Carcinoma Clinical Trial using Endurance exercise

Charite University, Berlin, Germany - Recruiting 18 years to 75 years.
- Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib).
Endurance exercise